BioCardia Statistics
Total Valuation
BioCardia has a market cap or net worth of $10.99 million. The enterprise value is $10.56 million.
Important Dates
The last earnings date was Monday, August 11, 2025, before market open.
Earnings Date | Aug 11, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
BioCardia has 5.80 million shares outstanding. The number of shares has increased by 163.54% in one year.
Current Share Class | 5.80M |
Shares Outstanding | 5.80M |
Shares Change (YoY) | +163.54% |
Shares Change (QoQ) | +9.15% |
Owned by Insiders (%) | 23.62% |
Owned by Institutions (%) | 5.59% |
Float | 4.33M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | n/a |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.33
Current Ratio | 0.33 |
Quick Ratio | 0.27 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | -222.28% |
Return on Invested Capital (ROIC) | n/a |
Return on Capital Employed (ROCE) | 570.12% |
Revenue Per Employee | n/a |
Profits Per Employee | -$439,700 |
Employee Count | 20 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -28.03% in the last 52 weeks. The beta is 0.81, so BioCardia's price volatility has been lower than the market average.
Beta (5Y) | 0.81 |
52-Week Price Change | -28.03% |
50-Day Moving Average | 2.14 |
200-Day Moving Average | 2.27 |
Relative Strength Index (RSI) | 43.87 |
Average Volume (20 Days) | 647,706 |
Short Selling Information
The latest short interest is 88,826, so 1.53% of the outstanding shares have been sold short.
Short Interest | 88,826 |
Short Previous Month | 191,112 |
Short % of Shares Out | 1.53% |
Short % of Float | 2.05% |
Short Ratio (days to cover) | 0.42 |
Income Statement
Revenue | n/a |
Gross Profit | -5.24M |
Operating Income | -8.85M |
Pretax Income | n/a |
Net Income | -8.79M |
EBITDA | -8.81M |
EBIT | -8.85M |
Earnings Per Share (EPS) | -$2.05 |
Full Income Statement Balance Sheet
The company has $980,000 in cash and $745,000 in debt, giving a net cash position of $235,000 or $0.04 per share.
Cash & Cash Equivalents | 980,000 |
Total Debt | 745,000 |
Net Cash | 235,000 |
Net Cash Per Share | $0.04 |
Equity (Book Value) | -1.89M |
Book Value Per Share | -0.34 |
Working Capital | -2.44M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$8.45 million and capital expenditures -$4,000, giving a free cash flow of -$8.46 million.
Operating Cash Flow | -8.45M |
Capital Expenditures | -4,000 |
Free Cash Flow | -8.46M |
FCF Per Share | -$1.46 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
BioCardia does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -163.54% |
Shareholder Yield | -163.54% |
Earnings Yield | -81.50% |
FCF Yield | -78.36% |
Analyst Forecast
The average price target for BioCardia is $25.00, which is 1,219.26% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $25.00 |
Price Target Difference | 1,219.26% |
Analyst Consensus | Strong Buy |
Analyst Count | 1 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
The last stock split was on May 30, 2024. It was a reverse split with a ratio of 1:15.
Last Split Date | May 30, 2024 |
Split Type | Reverse |
Split Ratio | 1:15 |
Scores
BioCardia has an Altman Z-Score of -124.44 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -124.44 |
Piotroski F-Score | 1 |